|Assessment Status||Assessment process complete|
|Indication||In combination with bendamustine followed by obinutuzumab maintenance for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended|
|Full pharmacoeconomic assessment commissioned by HSE||26/07/2016|
|NCPE assessment completed||25/01/2017|
|NCPE assessment outcome||Reimbursement not recommended at the submitted price|
The HSE has approved reimbursement following confidential price negotiations October 2017.